Regulating biotechnology: a rational-political model of policy development

Calingaert, 1988 Institute of Medicine, 1985 Banta, 1981 Laupacis, 1992, How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations, Canadian Medical Association Journal, 146, 473 Guyatt, 1995, Users' guide to the medical literature IX. A method for grading health care recommendations, Journal of the American Medical Association, 274, 1800, 10.1001/jama.1995.03530220066035 Carter, 1995, 153, 1715 Lowi, 1979 Schattschneider, 1975 Hall, 1986 Rosenberg, 1990, Gene Transfer into Humans—Immunotherapy of patients with advanced melanoma, using tumour-infiltrating lymphocytes modified by retroviral gene transduction, New England Journal of Medicine, 323, 570, 10.1056/NEJM199008303230904 Waldman, 1991, Monoclonal antibodies in diagnosis and therapy, Science, 252, 1657, 10.1126/science.2047874 Blank, 1989, Symposium: Political activities in biomedicine, 8, 341 Blumenthal, 1989, Genetic diagnosis, implications for medical practice, International Journal of Technology Assessment in Health Care, 5, 579, 10.1017/S0266462300008473 Pollack, 1988, The troubling cost of drugs that offer hope, New York Times, A1 Moloney, 1979, Medical technology—a different view of the contentious debate over costs, New England Journal of Medicine, 301, 1413, 10.1056/NEJM197912273012603 Macmillan, 1987, The cost-containment issue: A study of government-industry relations in the pharmaceutical sectors of the United Kingdom and Germany Nelson, 1977, In search of useful theory of innovation, Research Policy, 6, 36, 10.1016/0048-7333(77)90029-4 Feeny, 1986, New Health Technologies: Their effect on health and the cost of health care, 5 Deber, 1992, Translating technology assessment into policy, conceptual issues and tough choices, International Journal of Technology Assessment in Health Care, 8, 131, 10.1017/S0266462300007996 Lomas, 1993, Making clinical policy explicit: legislative policy making and lessons for developing practice guidelines, International Journal of Technology Assessment in Health Care, 9, 11, 10.1017/S0266462300002993 Greer, 1987, Rationing medical technology, International Journal of Technology Assessment in Health Care, 3, 199, 10.1017/S0266462300000519 Jennet, 1988, Assessment of clinical technologies, International Journal of Technology Assessment in Health Care, 4, 435, 10.1017/S0266462300000374 Wilson, 1980 Pross, 1992 Tiebilcock, 1978, Markets for regulation Tuohy, 1982, Regulation and scientific complexity: decision rules and processes in the occupational health area, Osgoode Hall Law Journal, 20, 562 Tuohy, 1985, Procedural rationality and regulatory Decision-Making: A decision framework approach, Law and Policy, 7, 345, 10.1111/j.1467-9930.1985.tb00357.x Heclo, 1978, Issue Networks and the Executive Establishment Hogwood, 1984 Coleman, 1990 Linton, 1990, Organized medicine and the assessment of technology, New England Journal of Medicine, 323, 1463, 10.1056/NEJM199011223232106 March, 1984, The New Institutionalism: Organization Factors in Political Life, American Political Science Review, 78, 734 Steinmo, 1989, Political Institutions and Tax Policy in the United States, Sweden and Britain, World Politics, 41, 500 Stokey, 1978 Arrow, 1963 Zeckhauser, 1978, Public Choice—To What Ends? Vickers, 1965 Stocking, 1988 Doern, 1988 Stone, 1988 Mitnick, 1980 Hancher, 1990 Wiktorowicz, 1995, Regulating Biotechnology: A Model of Rational-Political Policy Development Burns, 1986, Transactions and Social Structures, Vol. 2, 8 Dukes, 1990, The Importance of Adverse Reactions in Drug Regulation, Drug Safety, 5, 3 Atkinson, 1989, The Political Economy of Domestic Expansion: Pharmaceuticals Temin, 1984, Government actions in times of crisis: lessons from the history of drug regulation, Journal of Social History, 18, 433, 10.1353/jsh/18.3.433 Taylor, 1993, Policy on Licit Substances, Europe Without Frontiers? Balancing Pharmaceutical Interests, 283 Brickman, 1985 Weinberg, 1972, Science and Trans-Science, Minerva, 10, 209, 10.1007/BF01682418